Cadian Capital discloses 3.5% MaxCyte (MXCT) stake in latest 13G/A
Rhea-AI Filing Summary
MaxCyte, Inc. received an updated ownership report from Cadian Capital affiliates and Eric Bannasch. As of December 31, 2025, they may have been deemed to beneficially own 3,683,052 shares of MaxCyte common stock, representing approximately 3.5% of the company’s outstanding shares.
The shares are directly held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP, which are advisory clients of Cadian Capital Management, LP. The reporting parties state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MaxCyte.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What ownership stake in MaxCyte (MXCT) does Cadian report in this Schedule 13G/A?
Cadian-related reporting persons disclose beneficial ownership of 3,683,052 shares of MaxCyte common stock, equal to approximately 3.5% of outstanding shares as of December 31, 2025, based on 106,674,011 shares outstanding cited from MaxCyte’s Form 10-Q.
Who are the reporting persons in the MaxCyte (MXCT) Schedule 13G/A filing?
The filing lists Cadian Capital Management, LP, Cadian Capital Management GP, LLC, and Eric Bannasch as reporting persons. They report beneficial ownership through advisory clients Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP, over which Cadian Capital Management, LP exercises voting and investment power.
How is the 3.5% ownership in MaxCyte (MXCT) calculated in this filing?
The approximate 3.5% beneficial ownership is calculated using 3,683,052 shares of MaxCyte common stock over 106,674,011 shares outstanding as of November 7, 2025. That outstanding share figure comes from MaxCyte’s Form 10-Q filed on November 13, 2025.
Does the Cadian Schedule 13G/A indicate an intent to influence control of MaxCyte (MXCT)?
The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of MaxCyte. It also notes they are not held in connection with any control-related transaction.